For your treatment-naïve patients with RVO

START STRONG

STAY STRONG

Rapid benefits

In the COPERNICUS study, EYLEA® showed greater vision gains in patients treated within 2 months of diagnosis vs. those who first receive treatment >2 months after diagnosis1

Read more

Vision gains

Rapid, early vision gains are maintained through Year 1 in CRVO2,3 and BRVO,4 and Year 2 in CRVO5

Read more

Proactive T&E dosing

In the Casselholm study, EYLEA provided significantly reduced injection frequency by 24% vs. ranibizumab6

Read more

BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; T&E, treat-and-extend.

References

  1. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032.
  2. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121(1):202-208.
  3. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429-437.
  4. Clark WL, Boyer DS, Heier JS, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016;123(2):330-336.
  5. Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414-1420.
  6. Casselholm de Salles M, Amrén U, Kvanta A, et al. Injection frequency of aflibercept versus ranibizumab in a treat-and-extend regimen for central retinal vein occlusion. Retina. 2018; doi 10.1097/IAE.0000000000002171.